Mike is a Co-founder and Chief Scientific Officer of NeRRe, who recognised and championed the belief that next generation neurokinin-1 receptor antagonists such as the company’s lead clinical asset orvepitant could present an exciting new approach to effectively treat neuronal hypersensitivity disorders including chronic refractory cough. Mike was deeply involved in the acquisition of the Company’s neurokinin antagonist portfolio from GSK and the Series A fund raising to start NeRRe in 2012. He has an expert knowledge of neurokinin receptor system biology in general and in particular its connectivity to neuronal hypersensitivity disorders.
Mike is also Co-founder and CSO of KaNDy Therapeutics a Women’s Health company focussed on developing a unique dual mechanism neurokinin-1,3 receptor antagonism as a novel and truly transformational non-hormonal therapy for treatment of symptoms of the menopause and related Women’s Health conditions.
Prior to founding NeRRe, Mike worked in pharmaceutical industry R&D at GSK for nearly 20 years, where latterly he was VP & Head of the External Drug Discovery Group in the Neurosciences Centre for Excellence for Drug Discovery (CEDD). In this position successfully implemented the CEDD externalisation strategy and advanced a portfolio of preclinical and clinical pipeline assets.
Mike has BSc (Hons) and PhD degrees in biological sciences and has held post-doctoral positions at DuPont Inc in Delaware, US, and at the Medical Research Council in Cambridge, UK, under the Nobel laureate Professor Sydney Brenner.